关于伊维菌素作为新冠病毒潜在疗法的白皮书。
White paper on Ivermectin as a potential therapy for COVID-19.
作者信息
Vora Agam, Arora V K, Behera D, Tripathy Surya Kant
机构信息
Academy of Advanced Medical Education, Vora Clinic, 302, Soni Shopping Center, L T Road, Borivali West, Mumbai, 400092, Maharashtra, India.
Academy of Advanced Medical Education, Vora Clinic, 302, Soni Shopping Center, L T Road, Borivali West, Mumbai, 400092, Maharashtra, India.
出版信息
Indian J Tuberc. 2020 Jul;67(3):448-451. doi: 10.1016/j.ijtb.2020.07.031.
Abstract
A group of senior doctors with vast clinical experience met on 19th July'20 under the aegis of Academy of Advanced Medical Education. The panel looked at Ivermectin, one of the old molecule and evaluated it's use in COVID 19 (Novel Coronavirus Disease 2019) management. After critical panel discussion, all the attending doctors came to a conclusion that Ivermectin can be a potential molecule for prophylaxis and treatment of people infected with Coronavirus, owing to its anti-viral properties coupled with effective cost, availability and good tolerability and safety.
摘要
一群拥有丰富临床经验的资深医生于2020年7月19日在高级医学教育学院的支持下会面。该小组研究了伊维菌素这种老药，并评估了其在新冠疫情（2019年新型冠状病毒病）管理中的应用。经过小组的深入讨论，所有与会医生得出结论，由于伊维菌素有抗病毒特性，且成本效益高、易于获取、耐受性和安全性良好，它可能是预防和治疗冠状病毒感染者的一种有效药物。
相似文献
1
White paper on Ivermectin as a potential therapy for COVID-19.关于伊维菌素作为新冠病毒潜在疗法的白皮书。
Indian J Tuberc. 2020 Jul;67(3):448-451. doi: 10.1016/j.ijtb.2020.07.031.
2
The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.SARS-CoV-2 依维莫司纳瓦拉-ISGlobal 试验（SAINT）评估依维莫司在症状出现后 48 小时内降低低危、非重症 COVID-19 患者 COVID-19 传播风险的潜力：一项随机对照试验方案的研究方案结构化总结。
Trials. 2020 Jun 8;21(1):498. doi: 10.1186/s13063-020-04421-z.
3
Repurposing of host-based therapeutic agents for the treatment of coronavirus disease 2019 (COVID-19): a link between antiviral and anticancer mechanisms?基于宿主的治疗药物用于治疗2019冠状病毒病（COVID-19）：抗病毒机制与抗癌机制之间的联系？
Int J Antimicrob Agents. 2020 Sep;56(3):106125. doi: 10.1016/j.ijantimicag.2020.106125. Epub 2020 Jul 30.
4
Ivermectin: potential candidate for the treatment of Covid 19.伊维菌素：治疗新冠病毒病的潜在候选药物。
Braz J Infect Dis. 2020 Jul-Aug;24(4):369-371. doi: 10.1016/j.bjid.2020.06.002. Epub 2020 Jun 28.
5
Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action.伊维菌素、抗病毒特性和 COVID-19：一种可能的新作用机制。
Naunyn Schmiedebergs Arch Pharmacol. 2020 Jul;393(7):1153-1156. doi: 10.1007/s00210-020-01902-5. Epub 2020 May 27.
6
Mass Drug Administration and Worms Experience in Africa: Envisage Repurposing Ivermectin for SARS-COV-2.非洲大规模药物管理与蠕虫防治经验：设想将伊维菌素用于治疗新型冠状病毒肺炎（SARS-CoV-2）
Am J Trop Med Hyg. 2020 Jul;103(1):10-11. doi: 10.4269/ajtmh.20-0295. Epub 2020 May 26.
7
Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment?羟氯喹啉和伊维菌素：用于新冠病毒化学预防和治疗的协同组合？
J Am Acad Dermatol. 2020 Jun;82(6):e221. doi: 10.1016/j.jaad.2020.04.017. Epub 2020 Apr 10.
8
Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients.标准剂量伊维菌素对重症 COVID-19 患者无效。
PLoS One. 2020 Nov 11;15(11):e0242184. doi: 10.1371/journal.pone.0242184. eCollection 2020.
9
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.美国食品药品监督管理局批准的药物伊维菌素可抑制 SARS-CoV-2 的体外复制。
Antiviral Res. 2020 Jun;178:104787. doi: 10.1016/j.antiviral.2020.104787. Epub 2020 Apr 3.
10
Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19.伊维菌素可能是一种对晚期新冠肺炎有临床实用价值的抗炎药。
Open Heart. 2020 Sep;7(2). doi: 10.1136/openhrt-2020-001350.
引用本文的文献
1
Prediction of tsunami of resistance to some antibiotics is not far-fetched which used during COVID-19 pandemic.预测在新冠疫情期间使用的某些抗生素出现耐药性海啸并非牵强之事。
J Clin Lab Anal. 2023 Aug;37(15-16):e24959. doi: 10.1002/jcla.24959. Epub 2023 Aug 31.
2
Respiratory Distress with Minimal Exertion: A Case of 2019 Novel Coronavirus (COVID-19) Pneumonia.轻微活动后出现呼吸窘迫：一例2019新型冠状病毒（COVID-19）肺炎病例
HCA Healthc J Med. 2020 Nov 28;1:369-372. doi: 10.36518/2689-0216.1120. eCollection 2020.
3
Effect of Ivermectin prophylaxis in prevention of COVID 19: Meta-analysis and systematic review.伊维菌素预防对 COVID-19 预防的效果：荟萃分析与系统评价。
J Family Med Prim Care. 2022 Nov;11(11):6660-6667. doi: 10.4103/jfmpc.jfmpc_527_22. Epub 2022 Dec 16.
4
Clinical characteristics and outcome of patients presenting to emergency department during the second wave of COVID-19.第二波新冠疫情期间急诊科患者的临床特征与转归
J Family Med Prim Care. 2022 Jun;11(6):2723-2728. doi: 10.4103/jfmpc.jfmpc_1726_21. Epub 2022 Jun 30.
5
Potential therapeutic effects of Ivermectin in COVID-19.伊维菌素在 COVID-19 中的潜在治疗作用。
Exp Biol Med (Maywood). 2022 Aug;247(15):1388-1396. doi: 10.1177/15353702221099579. Epub 2022 Jun 10.
6
Combined therapy with ivermectin and doxycycline can effectively alleviate the cytokine storm of COVID-19 infection amid vaccination drive: A narrative review.伊维菌素和强力霉素联合治疗可有效缓解疫苗接种运动期间 COVID-19 感染的细胞因子风暴：叙述性评论。
J Infect Public Health. 2022 May;15(5):566-572. doi: 10.1016/j.jiph.2022.03.014. Epub 2022 Mar 30.
7
Repurposing the drug, ivermectin, in COVID-19: toxicological points of view.重新利用药物伊维菌素治疗 COVID-19：毒理学观点。
Eur J Med Res. 2022 Feb 5;27(1):21. doi: 10.1186/s40001-022-00645-8.
8
COVID-19 and antimicrobial resistance: A cross-study.新型冠状病毒肺炎与抗菌药物耐药性：一项跨研究分析。
Sci Total Environ. 2022 Feb 10;807(Pt 2):150873. doi: 10.1016/j.scitotenv.2021.150873. Epub 2021 Oct 8.
9
Ivermectin as a multifaceted drug in COVID-19: Current insights.
Med J Armed Forces India. 2021 Jul;77(Suppl 2):S254-S256. doi: 10.1016/j.mjafi.2021.06.002. Epub 2021 Jul 26.
10
A Large Impact of Obesity on the Disposition of Ivermectin, Moxidectin and Eprinomectin in a Canine Model: Relevance for COVID-19 Patients.肥胖对伊维菌素、莫西菌素和埃普利诺菌素在犬类模型中处置的重大影响：对COVID-19患者的相关性
Front Pharmacol. 2021 May 20;12:666348. doi: 10.3389/fphar.2021.666348. eCollection 2021.
本文引用的文献
1
Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study.使用伊维菌素与 COVID-19 住院患者的死亡率降低相关：COVID-19 中的伊维菌素研究。
Chest. 2021 Jan;159(1):85-92. doi: 10.1016/j.chest.2020.10.009. Epub 2020 Oct 13.
2
COVID-19 Pandemic in India: Present Scenario and a Steep Climb Ahead.印度的新冠疫情：现状与未来的艰难攀升
J Prim Care Community Health. 2020 Jan-Dec;11:2150132720939402. doi: 10.1177/2150132720939402.
3
Ivermectin: potential candidate for the treatment of Covid 19.伊维菌素：治疗新冠病毒病的潜在候选药物。
Braz J Infect Dis. 2020 Jul-Aug;24(4):369-371. doi: 10.1016/j.bjid.2020.06.002. Epub 2020 Jun 28.
4
The Battle against COVID 19 Pandemic: What we Need to Know Before we "Test Fire" Ivermectin.抗击新冠疫情：在我们“试用”伊维菌素之前我们需要了解的事情。
Drug Res (Stuttg). 2020 Aug;70(8):337-340. doi: 10.1055/a-1185-8913. Epub 2020 Jun 19.
5
Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen.伊维菌素：从抗病毒作用到 COVID-19 补充治疗方案的系统评价。
J Antibiot (Tokyo). 2020 Sep;73(9):593-602. doi: 10.1038/s41429-020-0336-z. Epub 2020 Jun 12.
6
SARS-CoV-2 and COVID-19: From the Bench to the Bedside.SARS-CoV-2 和 COVID-19：从实验室到临床。
Physiol Rev. 2020 Oct 1;100(4):1455-1466. doi: 10.1152/physrev.00020.2020. Epub 2020 Jun 4.
7
Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19.伊维菌素，一种治疗新型冠状病毒/新冠肺炎的新候选药物。
Ann Clin Microbiol Antimicrob. 2020 May 30;19(1):23. doi: 10.1186/s12941-020-00368-w.
8
Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data.羟氯喹治疗需要吸氧的 COVID-19 肺炎患者的临床疗效：利用常规护理数据进行的观察性对比研究。
BMJ. 2020 May 14;369:m1844. doi: 10.1136/bmj.m1844.
9
Perspectives for repurposing drugs for the coronavirus disease 2019.用于 2019 年冠状病毒疾病的药物再利用视角。
Indian J Med Res. 2020;151(2 & 3):160-171. doi: 10.4103/ijmr.IJMR_585_20.
10
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.美国食品药品监督管理局批准的药物伊维菌素可抑制 SARS-CoV-2 的体外复制。
Antiviral Res. 2020 Jun;178:104787. doi: 10.1016/j.antiviral.2020.104787. Epub 2020 Apr 3.
Zotero 插件